Statins and CVD Prevention in UK Primary Care 2026: What NICE NG238 Means in Practice

One guideline shapes how UK primary care prescribes statins in 2026: NICE NG238. Its lipid pathway reframed the QRISK3 threshold as a prompt for a shared decision rather than a gate, and it sets clear cholesterol aims for both primary and secondary prevention. None of it is a wholesale rewrite — but it sharpens a decision GPs make many times a week.

This is the practical picture: who to offer a statin to, at what dose, what to aim for, and where the conversation usually stalls. It is written for UK GPs, GP registrars, GP pharmacists, advanced clinical practitioners, and trainees. The NICE guideline and the BNF remain the authoritative references; this post summarises and links, it does not substitute for clinical judgement.

The QRISK3 threshold is a prompt, not a gate

NICE NG238 recommends offering atorvastatin 20mg for the primary prevention of cardiovascular disease to people with a 10-year QRISK3 score of 10% or more. QRISK3 is the tool for adults aged 25 to 84 without established cardiovascular disease, and it captures risk factors the older calculators missed — including severe mental illness, systemic lupus erythematosus, corticosteroid and atypical antipsychotic use, and migraine.

The change that matters in practice is what NICE says below 10%. The guidance is explicit: do not rule out atorvastatin 20mg just because someone's QRISK3 score is under 10%, if they have an informed preference for taking a statin. The 10% figure is the point at which you proactively raise it — not a line below which the answer is no. The decision becomes a conversation, not an arithmetic test.

The doses that matter

Primary prevention starts at atorvastatin 20mg. There is no titration ritual to reach it; 20mg is the starting dose.

Secondary prevention — anyone with established cardiovascular disease — is high-intensity treatment with atorvastatin 80mg, stepping down only where drug interactions, a high risk of adverse effects, or patient preference make the full dose unsuitable. The distinction between the 20mg primary-prevention dose and the 80mg secondary-prevention dose is the one most worth holding clearly, because it is the one most often blurred at the point of prescribing.

What you are aiming for

The aim differs between primary and secondary prevention, and the distinction is worth holding clearly. For primary prevention, NICE NG238 sets a relative aim: a greater than 40% reduction in non-HDL cholesterol. For secondary prevention — anyone with established cardiovascular disease — it sets absolute targets: an LDL cholesterol of 2.0 mmol/L or less, or a non-HDL cholesterol of 2.6 mmol/L or less. A full lipid profile is checked at 2 to 3 months after starting or changing treatment.

These are aims to act on, not just to record. If the target is not reached at review, the prompt is a real conversation — about adherence first, then lifestyle, then dose — rather than a shrug or an automatic switch. Most of the missing benefit in lipid management is not a wrong drug; it is a drug that is not being taken.

Statins in diabetes

Diabetes is a major cardiovascular risk factor, and lipid management in this group is a recurring primary-care focus — in NG238 and in the QOF alike. The practical goal is to make sure eligible patients with diabetes are actually on appropriate lipid-lowering therapy; the current QOF business rules hold the precise indicator wording and thresholds.

In practice this is register work. A targeted search of the diabetes register for patients not on a statin — and for those on a statin but without a recorded response to treatment — is the highest-yield use of the time.

Where the conversation stalls

The pharmacology is settled. The friction is human.

Statin hesitancy is real and worth meeting directly rather than dismissing. The most common sticking point is muscle symptoms, where the nocebo effect is well described: many symptoms attributed to a statin recur on placebo. That does not mean every complaint is imagined — it means the right response is a structured one, including a treatment break and rechallenge, rather than a permanent label of intolerance after a single episode.

The second sticking point is the framing of risk itself. A 10-year cardiovascular risk number is abstract; a clear sentence about what the treatment does — and how long it takes to do it — earns more adherence than a percentage ever will.

A note on what this post is — and is not

This is a guideline summary for awareness. It is not a substitute for NICE NG238, the BNF, the QOF business rules, or local prescribing policy. Thresholds, doses, and indicator definitions change and should be confirmed before prescribing. Clinical decisions remain the responsibility of the prescribing clinician.

The Monday Clinical Brief publishes weekly summaries of the most important new papers and guideline updates across 31 UK medical specialties — including prescribing and policy changes like this one. We surface them, summarise them, and link to them, so practice-changing material does not get missed in a busy clinical week.

Related reading

• NICE NG28 February 2026: SGLT2 inhibitors first-line for type 2 diabetes — the diabetes update that sits alongside lipid management in cardiovascular risk reduction.
• SGLT2 inhibitors for CKD in UK primary care 2026 (TA1075) — kidney protection in the same high-cardiovascular-risk population.
• Anticoagulation in atrial fibrillation: a UK primary-care guide (NG196) — the other major stroke-prevention decision in primary care.

Subscribe to The Monday Clinical Brief — £20 a year, no advertising, no sponsored content, just every week's most important reading delivered to your inbox on Monday morning.